ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran

Benefits of Slowing the Heart with Ivabradine

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Cardiogenic Shock: Should IABP or PVADs Be Used in Cardiogenic Shock?

American Heart & Vascular Institute

M. Ansari

ACC 2024 Insights: Stop the Meds! Treat the Comorbidities for Optima…

ACC 2024 Insights

K. Williams

High-Risk Cardiac Surgery and Pre-Op Optimization with Impella Base …

St. Louis Shock & Heart Failure Symposium 2022

J. Leidenfrost

Medical Management of Diastolic Dysfunction: Does The Emperor Finall…

Top Ten Topics in Clinical Cardiology 2023

S. Pinney